Clinical Trials Logo
  1. Home
  2. Asthma, Aspirin-Induced
  3. NCT02824523

Role of Inflammatory Mediators in AERD

Asthma, Aspirin-Induced Clinical Trial

Official title:
Role of PDG2 in the Aspirin-Induced Reactions and in the Treatment of Aspirin-Exacerbated Respiratory Disease

Clinical Trial Summary

The purpose of this research study is to learn new information about the underlying cause of aspirin-exacerbated respiratory disease (AERD) and the benefit of high-dose aspirin therapy. AERD is a disease that involves asthma, recurring nasal polyps, and respiratory reactions to aspirin and other nonsteroidal anti-inflammatory drugs. This study will be conducted on individuals with AERD who are referred to the Brigham and Women's Hospital AERD Center for clinical evaluation and potential aspirin desensitization. Desensitization to aspirin and subsequent treatment with daily high-dose oral aspirin is standard of care for patients with AERD who do not respond adequately to steroids and have recurrent nasal polyposis or symptomatic asthma. This study will involve five visits to Brigham and Women's Hospital and will align closely with the standard of care for the treatment of AERD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02824523
Study type Observational
Source Brigham and Women's Hospital
Contact
Status Completed
Phase
Start date July 2016
Completion date May 1, 2021
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT01681615 - Challenge Test for Acetylsalicylic Acid Hypersensitivity N/A
Terminated NCT01320072 - Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease
Completed NCT01867281 - The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases Phase 4
Active, not recruiting NCT03028350 - Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) Phase 2
Completed NCT01597375 - Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin) Phase 2
Recruiting NCT04823585 - Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab) N/A
Recruiting NCT05575037 - Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease Phase 2
Completed NCT03326063 - Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban Phase 2